Alumis (ALMS) vs ArriVent BioPharma (AVBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alumis (ALMS) has outperformed ArriVent BioPharma (AVBP) over the past year, gaining 50.1% versus a loss of 12.5%. Alumis is the larger company by market cap ($884.7 million vs $814.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALMS | AVBP |
|---|---|---|
| Share price | $6.84 | $16.51 |
| Market cap | $884.69M | $814.07M |
| 1-day change | +0.96% | -2.25% |
| YTD return | -30.64% | -16.05% |
| 1-year return | +50.11% | -12.53% |
| EPS (TTM) | $-3.86 | $-3.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.35 | $35.83 |
| 52-week low | $4.28 | $11.36 |
| Distance from 52-week high | -78.20% | -53.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +370.08% | +84.74% |
| Average volume | 2.43M | 881.59K |
| Shares outstanding | 129.44M | 49.31M |
| Employees | 237 | 77 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALMS has outperformed AVBP by 62.6 percentage points over the past year.
About Alumis
ALMS stock →Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 237 employees
About ArriVent BioPharma
AVBP stock →ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 77 employees
ALMS vs AVBP FAQ
Which is bigger, Alumis or ArriVent BioPharma?
Alumis (ALMS) is larger, with a market capitalization of $884.69M compared with $814.07M for ArriVent BioPharma (AVBP).
Which stock has performed better over the past year, ALMS or AVBP?
ALMS returned +50.11% over the past 12 months, compared with -12.53% for AVBP (price return, excluding dividends). Past performance does not predict future results.
Are Alumis and ArriVent BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.